Cite
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
MLA
Shi, Yuankai, et al. “Results of the Phase IIa Study to Evaluate the Efficacy and Safety of Rezivertinib (BPI-7711) for the First-Line Treatment of Locally Advanced or Metastatic/Recurrent NSCLC Patients with EGFR Mutation from a Phase I/IIa Study.” BMC Medicine, vol. 21, no. 1, Jan. 2023, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12916-022-02692-8.
APA
Shi, Y., Zhou, J., Zhao, Y., Zhu, B., Zhang, L., Li, X., Fang, J., Shi, J., Zhuang, Z., Yang, S., Wang, D., Yu, H., Zhang, L., Zheng, R., Greco, M., & Wang, T. (2023). Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC Medicine, 21(1), 1–13. https://doi.org/10.1186/s12916-022-02692-8
Chicago
Shi, Yuankai, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, et al. 2023. “Results of the Phase IIa Study to Evaluate the Efficacy and Safety of Rezivertinib (BPI-7711) for the First-Line Treatment of Locally Advanced or Metastatic/Recurrent NSCLC Patients with EGFR Mutation from a Phase I/IIa Study.” BMC Medicine 21 (1): 1–13. doi:10.1186/s12916-022-02692-8.